| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 255.796 | 354.446 | 319.442 | 323.091 | 339.172 | 528.656 | 623.241 | 718.166 | 847.417 | 773.300 |
| Total Income - EUR | 280.758 | 367.585 | 320.077 | 325.196 | 339.875 | 529.461 | 624.133 | 719.134 | 848.157 | 773.920 |
| Total Expenses - EUR | 279.408 | 366.534 | 312.993 | 321.294 | 334.290 | 506.071 | 585.191 | 693.163 | 837.957 | 764.753 |
| Gross Profit/Loss - EUR | 1.351 | 1.051 | 7.084 | 3.902 | 5.585 | 23.390 | 38.942 | 25.971 | 10.200 | 9.167 |
| Net Profit/Loss - EUR | 889 | 547 | 4.162 | 973 | 2.187 | 18.483 | 33.450 | 19.836 | 4.686 | 6.020 |
| Employees | 4 | 4 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 3 |
Check the financial reports for the company - Melagrana Pharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 871 | 511 | 175 | 613 | 2.465 | 1.439 | 33.699 | 24.269 |
| Current Assets | 111.747 | 80.961 | 88.726 | 104.114 | 109.008 | 152.528 | 210.174 | 305.470 | 201.152 | 277.787 |
| Inventories | 54.795 | 37.618 | 39.433 | 43.919 | 50.197 | 66.823 | 79.792 | 99.303 | 92.897 | 87.126 |
| Receivables | 55.963 | 27.807 | 40.613 | 57.207 | 53.415 | 69.609 | 93.087 | 174.085 | 97.674 | 178.486 |
| Cash | 990 | 15.536 | 8.680 | 2.989 | 5.396 | 16.096 | 37.295 | 32.082 | 10.581 | 12.174 |
| Shareholders Funds | 2.176 | 2.701 | 6.818 | 6.308 | 6.154 | 21.474 | 43.765 | 55.199 | 54.488 | 56.051 |
| Social Capital | 382 | 379 | 372 | 365 | 358 | 351 | 344 | 345 | 344 | 342 |
| Debts | 112.239 | 80.597 | 89.134 | 101.059 | 106.286 | 132.266 | 171.099 | 252.277 | 181.131 | 249.109 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Melagrana Pharm Srl